The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2025
Synopsis
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Benign Prostatic Hyperplasia (BPH) Medication market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4228.2 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Medication.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Medication market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Medication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Segment by Type
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
The global Benign Prostatic Hyperplasia (BPH) Medication market was valued at US$ 3329.5 million in 2023 and is anticipated to reach US$ 4228.2 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Medication.
Report Scope
The Benign Prostatic Hyperplasia (BPH) Medication market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Benign Prostatic Hyperplasia (BPH) Medication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Benign Prostatic Hyperplasia (BPH) Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Segment by Type
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Medication
1.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Value Comparison by Type (2024-2030)
1.2.2 5-Alpha-Reductase Inhibitors
1.2.3 Beta-Blockers
1.2.4 Botanicals and Traditional Chinese Medicine
1.3 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue 2019-2030
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales 2019-2030
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Benign Prostatic Hyperplasia (BPH) Medication Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2019-2024)
2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Manufacturers (2019-2024)
2.4 Global Benign Prostatic Hyperplasia (BPH) Medication Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, Product Type & Application
2.7 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation and Trends
2.7.1 Benign Prostatic Hyperplasia (BPH) Medication Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue
2.7.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Medication Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region: 2019-2030
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region: 2019-2024
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region: 2025-2030
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2019-2030
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2019-2024
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2025-2030
3.4 North America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.4.1 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2030)
3.4.3 North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.5.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2030)
3.5.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2030)
3.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2030)
3.7.3 Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Facts & Figures by Country
3.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2030)
3.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2019-2030)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2019-2024)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2025-2030)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2019-2030)
4.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2019-2030)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2019-2024)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2025-2030)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2019-2030)
4.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2019-2030)
5 Segment by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2019-2030)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2019-2024)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2025-2030)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2019-2030)
5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2019-2030)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2019-2024)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2025-2030)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2019-2030)
5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Astellas Pharma
6.1.1 Astellas Pharma Corporation Information
6.1.2 Astellas Pharma Description and Business Overview
6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.1.5 Astellas Pharma Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 ADC Therapeutics
6.5.1 ADC Therapeutics Corporation Information
6.5.2 ADC Therapeutics Description and Business Overview
6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.5.5 ADC Therapeutics Recent Developments/Updates
6.6 Bayer HealthCare
6.6.1 Bayer HealthCare Corporation Information
6.6.2 Bayer HealthCare Description and Business Overview
6.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.6.5 Bayer HealthCare Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Valeant Pharmaceuticals
6.8.1 Valeant Pharmaceuticals Corporation Information
6.8.2 Valeant Pharmaceuticals Description and Business Overview
6.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.8.5 Valeant Pharmaceuticals Recent Developments/Updates
6.9 Endo Pharmaceuticals
6.9.1 Endo Pharmaceuticals Corporation Information
6.9.2 Endo Pharmaceuticals Description and Business Overview
6.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.9.5 Endo Pharmaceuticals Recent Developments/Updates
6.10 Foresee Pharmaceuticals
6.10.1 Foresee Pharmaceuticals Corporation Information
6.10.2 Foresee Pharmaceuticals Description and Business Overview
6.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.10.5 Foresee Pharmaceuticals Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.11.5 Merck Recent Developments/Updates
6.12 Novartis
6.12.1 Novartis Corporation Information
6.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.12.5 Novartis Recent Developments/Updates
6.13 Advaxis
6.13.1 Advaxis Corporation Information
6.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.13.5 Advaxis Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.15 Urologixs
6.15.1 Urologixs Corporation Information
6.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.15.5 Urologixs Recent Developments/Updates
6.16 Agennix
6.16.1 Agennix Corporation Information
6.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.16.5 Agennix Recent Developments/Updates
6.17 ANI Pharmaceuticals
6.17.1 ANI Pharmaceuticals Corporation Information
6.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.17.5 ANI Pharmaceuticals Recent Developments/Updates
6.18 BHR Pharma
6.18.1 BHR Pharma Corporation Information
6.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.18.5 BHR Pharma Recent Developments/Updates
6.19 Boehringer Ingelheim
6.19.1 Boehringer Ingelheim Corporation Information
6.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.19.5 Boehringer Ingelheim Recent Developments/Updates
6.20 Sanpower Group
6.20.1 Sanpower Group Corporation Information
6.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.20.5 Sanpower Group Recent Developments/Updates
6.21 Eisai
6.21.1 Eisai Corporation Information
6.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.21.5 Eisai Recent Developments/Updates
6.22 Ferring
6.22.1 Ferring Corporation Information
6.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.22.5 Ferring Recent Developments/Updates
6.23 IO THERAPEUTICS
6.23.1 IO THERAPEUTICS Corporation Information
6.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.23.5 IO THERAPEUTICS Recent Developments/Updates
6.24 LIDDS
6.24.1 LIDDS Corporation Information
6.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.24.5 LIDDS Recent Developments/Updates
6.25 Madrigal Pharmaceuticals
6.25.1 Madrigal Pharmaceuticals Corporation Information
6.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.25.5 Madrigal Pharmaceuticals Recent Developments/Updates
6.26 Nymox Pharmaceutical
6.26.1 Nymox Pharmaceutical Corporation Information
6.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.26.5 Nymox Pharmaceutical Recent Developments/Updates
6.27 Spectrum Pharmaceuticals
6.27.1 Spectrum Pharmaceuticals Corporation Information
6.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.27.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.28 Takeda Pharmaceuticals
6.28.1 Takeda Pharmaceuticals Corporation Information
6.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Description and Business Overview
6.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue and Gross Margin (2019-2024)
6.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolio
6.28.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
7.2 Benign Prostatic Hyperplasia (BPH) Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Benign Prostatic Hyperplasia (BPH) Medication Production Mode & Process
7.4 Benign Prostatic Hyperplasia (BPH) Medication Sales and Marketing
7.4.1 Benign Prostatic Hyperplasia (BPH) Medication Sales Channels
7.4.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors
7.5 Benign Prostatic Hyperplasia (BPH) Medication Customers
8 Benign Prostatic Hyperplasia (BPH) Medication Market Dynamics
8.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Trends
8.2 Benign Prostatic Hyperplasia (BPH) Medication Market Drivers
8.3 Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
8.4 Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Medication Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Medication Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation by Manufacturers in 2023
Table 4. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) of Key Manufacturers (2019-2024)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Benign Prostatic Hyperplasia (BPH) Medication, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, Product Type & Application
Table 12. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Medication, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Medication as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2019-2024) & (KG)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2019-2024)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2025-2030) & (KG)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2025-2030)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2019-2024)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2025-2030)
Table 25. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2024) & (KG)
Table 27. North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2025-2030) & (KG)
Table 28. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2024) & (KG)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2025-2030) & (KG)
Table 33. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2019-2024) & (KG)
Table 37. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2025-2030) & (KG)
Table 38. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2024) & (KG)
Table 42. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2025-2030) & (KG)
Table 43. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2019-2024) & (KG)
Table 47. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2025-2030) & (KG)
Table 48. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2019-2024)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Type (2025-2030)
Table 52. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2019-2024)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2025-2030)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2019-2024)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2025-2030)
Table 58. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2019-2024)
Table 59. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2025-2030)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2019-2024)
Table 61. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG) by Application (2025-2030)
Table 62. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2019-2024)
Table 63. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2025-2030)
Table 64. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2019-2024)
Table 67. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2025-2030)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2019-2024)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2025-2030)
Table 70. Astellas Pharma Corporation Information
Table 71. Astellas Pharma Description and Business Overview
Table 72. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 73. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 74. Astellas Pharma Recent Developments/Updates
Table 75. Eli Lilly Corporation Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 78. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 83. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product
Table 84. GlaxoSmithKline Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 88. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product
Table 89. Sanofi Recent Developments/Updates
Table 90. ADC Therapeutics Corporation Information
Table 91. ADC Therapeutics Description and Business Overview
Table 92. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 93. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product
Table 94. ADC Therapeutics Recent Developments/Updates
Table 95. Bayer HealthCare Corporation Information
Table 96. Bayer HealthCare Description and Business Overview
Table 97. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 98. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product
Table 99. Bayer HealthCare Recent Developments/Updates
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 103. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product
Table 104. Bristol-Myers Squibb Recent Developments/Updates
Table 105. Valeant Pharmaceuticals Corporation Information
Table 106. Valeant Pharmaceuticals Description and Business Overview
Table 107. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 108. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 109. Valeant Pharmaceuticals Recent Developments/Updates
Table 110. Endo Pharmaceuticals Corporation Information
Table 111. Endo Pharmaceuticals Description and Business Overview
Table 112. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 113. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 114. Endo Pharmaceuticals Recent Developments/Updates
Table 115. Foresee Pharmaceuticals Corporation Information
Table 116. Foresee Pharmaceuticals Description and Business Overview
Table 117. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 118. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 119. Foresee Pharmaceuticals Recent Developments/Updates
Table 120. Merck Corporation Information
Table 121. Merck Description and Business Overview
Table 122. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 123. Merck Benign Prostatic Hyperplasia (BPH) Medication Product
Table 124. Merck Recent Developments/Updates
Table 125. Novartis Corporation Information
Table 126. Novartis Description and Business Overview
Table 127. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 128. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 129. Novartis Recent Developments/Updates
Table 130. Advaxis Corporation Information
Table 131. Advaxis Description and Business Overview
Table 132. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 133. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product
Table 134. Advaxis Recent Developments/Updates
Table 135. Teva Pharmaceutical Industries Corporation Information
Table 136. Teva Pharmaceutical Industries Description and Business Overview
Table 137. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 138. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product
Table 139. Teva Pharmaceutical Industries Recent Developments/Updates
Table 140. Urologixs Corporation Information
Table 141. Urologixs Description and Business Overview
Table 142. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 143. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product
Table 144. Urologixs Recent Developments/Updates
Table 145. Agennix Corporation Information
Table 146. Agennix Description and Business Overview
Table 147. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 148. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product
Table 149. Agennix Recent Developments/Updates
Table 150. ANI Pharmaceuticals Corporation Information
Table 151. ANI Pharmaceuticals Description and Business Overview
Table 152. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 153. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 154. ANI Pharmaceuticals Recent Developments/Updates
Table 155. BHR Pharma Corporation Information
Table 156. BHR Pharma Description and Business Overview
Table 157. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 158. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product
Table 159. BHR Pharma Recent Developments/Updates
Table 160. Boehringer Ingelheim Corporation Information
Table 161. Boehringer Ingelheim Description and Business Overview
Table 162. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 163. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product
Table 164. Boehringer Ingelheim Recent Developments/Updates
Table 165. Sanpower Group Corporation Information
Table 166. Sanpower Group Description and Business Overview
Table 167. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 168. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product
Table 169. Sanpower Group Recent Developments/Updates
Table 170. Eisai Corporation Information
Table 171. Eisai Description and Business Overview
Table 172. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 173. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product
Table 174. Eisai Recent Developments/Updates
Table 175. Ferring Corporation Information
Table 176. Ferring Description and Business Overview
Table 177. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 178. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product
Table 179. Ferring Recent Developments/Updates
Table 180. IO THERAPEUTICS Corporation Information
Table 181. IO THERAPEUTICS Description and Business Overview
Table 182. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 183. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product
Table 184. IO THERAPEUTICS Recent Developments/Updates
Table 185. LIDDS Corporation Information
Table 186. LIDDS Description and Business Overview
Table 187. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 188. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product
Table 189. LIDDS Recent Developments/Updates
Table 190. Madrigal Pharmaceuticals Corporation Information
Table 191. Madrigal Pharmaceuticals Description and Business Overview
Table 192. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 193. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 194. Madrigal Pharmaceuticals Recent Developments/Updates
Table 195. Nymox Pharmaceutical Corporation Information
Table 196. Nymox Pharmaceutical Description and Business Overview
Table 197. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 198. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product
Table 199. Nymox Pharmaceutical Recent Developments/Updates
Table 200. Spectrum Pharmaceuticals Corporation Information
Table 201. Spectrum Pharmaceuticals Description and Business Overview
Table 202. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 203. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 204. Spectrum Pharmaceuticals Recent Developments/Updates
Table 205. Takeda Pharmaceuticals Corporation Information
Table 206. Takeda Pharmaceuticals Description and Business Overview
Table 207. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2019-2024)
Table 208. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product
Table 209. Takeda Pharmaceuticals Recent Developments/Updates
Table 210. Key Raw Materials Lists
Table 211. Raw Materials Key Suppliers Lists
Table 212. Benign Prostatic Hyperplasia (BPH) Medication Distributors List
Table 213. Benign Prostatic Hyperplasia (BPH) Medication Customers List
Table 214. Benign Prostatic Hyperplasia (BPH) Medication Market Trends
Table 215. Benign Prostatic Hyperplasia (BPH) Medication Market Drivers
Table 216. Benign Prostatic Hyperplasia (BPH) Medication Market Challenges
Table 217. Benign Prostatic Hyperplasia (BPH) Medication Market Restraints
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Medication
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Medication Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Type in 2023 & 2030
Figure 4. 5-Alpha-Reductase Inhibitors Product Picture
Figure 5. Beta-Blockers Product Picture
Figure 6. Botanicals and Traditional Chinese Medicine Product Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Medication Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Medication Market Share by Application in 2023 & 2030
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (2019-2030) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Medication Sales (2019-2030) & (KG)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Medication Average Price (USD/KG) & (2019-2030)
Figure 16. Benign Prostatic Hyperplasia (BPH) Medication Report Years Considered
Figure 17. Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Manufacturers in 2023
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players: Market Share by Revenue in 2023
Figure 20. Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2019-2030)
Figure 23. North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2019-2030)
Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2019-2030)
Figure 28. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2019-2030)
Figure 35. China Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2019-2030)
Figure 46. Latin America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Medication by Type (2019-2030)
Figure 56. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Medication by Type (2019-2030)
Figure 57. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Type (2019-2030)
Figure 58. Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Medication by Application (2019-2030)
Figure 59. Global Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Medication by Application (2019-2030)
Figure 60. Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG) by Application (2019-2030)
Figure 61. Benign Prostatic Hyperplasia (BPH) Medication Value Chain
Figure 62. Benign Prostatic Hyperplasia (BPH) Medication Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
